home / stock / akba / akba quote
Last: | $1.44 |
---|---|
Change Percent: | -2.7% |
Open: | $1.52 |
Close: | $1.44 |
High: | $1.52 |
Low: | $1.41 |
Volume: | 1,132,793 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.44 | $1.52 | $1.44 | $1.52 | $1.41 | 1,132,793 | 07-26-2024 |
$1.48 | $1.48 | $1.48 | $1.52 | $1.41 | 2,334,431 | 07-25-2024 |
$1.47 | $1.43 | $1.47 | $1.5686 | $1.4243 | 3,011,278 | 07-24-2024 |
$1.46 | $1.35 | $1.46 | $1.46 | $1.34 | 2,357,574 | 07-23-2024 |
$1.38 | $1.36 | $1.38 | $1.39 | $1.3 | 2,013,210 | 07-22-2024 |
$1.35 | $1.35 | $1.35 | $1.37 | $1.3 | 1,881,964 | 07-19-2024 |
$1.36 | $1.39 | $1.36 | $1.4499 | $1.34 | 2,217,463 | 07-18-2024 |
$1.41 | $1.4 | $1.41 | $1.43 | $1.32 | 2,389,624 | 07-17-2024 |
$1.42 | $1.35 | $1.42 | $1.46 | $1.31 | 3,792,073 | 07-16-2024 |
$1.31 | $1.27 | $1.31 | $1.32 | $1.24 | 2,998,441 | 07-15-2024 |
$1.26 | $1.27 | $1.26 | $1.34 | $1.17 | 5,177,683 | 07-12-2024 |
$1.27 | $1.15 | $1.27 | $1.27 | $1.08 | 5,098,010 | 07-11-2024 |
$1.08 | $0.985 | $1.08 | $1.08 | $0.9849 | 1,820,496 | 07-10-2024 |
$0.9772 | $0.93 | $0.9772 | $1 | $0.93 | 2,840,030 | 07-09-2024 |
$0.948 | $0.95 | $0.948 | $0.9999 | $0.9228 | 2,358,004 | 07-08-2024 |
$0.9357 | $0.94 | $0.9357 | $0.945 | $0.91 | 1,780,020 | 07-05-2024 |
$0.9465 | $0.9669 | $0.9465 | $0.9693 | $0.9334 | 1,366,606 | 07-04-2024 |
$0.9465 | $0.9669 | $0.9465 | $0.969299 | $0.9334 | 1,366,606 | 07-03-2024 |
$0.96 | $0.9798 | $0.96 | $0.9946 | $0.9203 | 3,298,198 | 07-02-2024 |
$0.9944 | $1.03 | $0.9944 | $1.05 | $0.9707 | 4,350,843 | 07-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Akebia Therapeutics Inc. Company Name:
AKBA Stock Symbol:
NASDAQ Market:
Akebia Therapeutics Inc. Website:
Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets PR Newswire Akebia regains full rights to sell Vafseo® (vadadustat) Tablets in the U.S. following the execution of a royalty-based termination agreement wit...
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference PR Newswire CAMBRIDGE, Mass. , June 27, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purp...
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer PR Newswire CAMBRIDGE, Mass. , June 24, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with t...